Literature DB >> 32558721

177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept.

Arunav Kumar1, Sanjana Ballal1, Madhav Prasad Yadav1, S T ArunRaj1, K P Haresh2, Subhash Gupta2, Nishikant Avinash Damle1, Ajay Garg3, Madhavi Tripathi1, Chandrasekhar Bal1.   

Abstract

A 37-year-old man, treated case of left temporal glioblastoma presented with headache, seizures, and progressive right-sided weakness with MRI evidence of recurrence. Exploratory Ga-PSMA PET/CT demonstrated PSMA expression in the recurrent lesion; it was decided to treat this patient with Lu-PSMA-617. After 3 cycles of Lu-PSMA-617, Ga-PSMA PET/CT showed significant reduction in PSMA uptake and regression in size of lesion on MRI with improvement in patient's symptoms and performance status. Lu-/Ga-PSMA theranostics has potential in patients with recurrent glioblastoma multiforme when other therapeutic options are not feasible.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32558721     DOI： 10.1097/RLU.0000000000003142

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  8 in total

1.  Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo.

Authors:  Arunav Kumar; Sreedharan Thankarajan ArunRaj; Khush Bhullar; K P Haresh; Subhash Gupta; Sanjana Ballal; Madhav Yadav; Manmohan Singh; Nishikant Avinash Damle; Ajay Garg; Madhavi Tripathi; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2021-10-14       Impact factor: 2.804

2.  PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers.

Authors:  Shuxian An; Gang Huang; Jianjun Liu; Weijun Wei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-10       Impact factor: 10.057

Review 3.  Novel Tracers and Radionuclides in PET Imaging.

Authors:  Christian Mason; Grayson R Gimblet; Suzanne E Lapi; Jason S Lewis
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

Review 4.  PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area.

Authors:  Antoine Verger; Aurélie Kas; Jacques Darcourt; Eric Guedj
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 5.  Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.

Authors:  Brittany M Stopa; James Crowley; Csaba Juhász; Cara M Rogers; Mark R Witcher; Jackson W Kiser
Journal:  Mol Imaging       Date:  2022-04-15       Impact factor: 3.250

Review 6.  Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis.

Authors:  Barbara Muoio; Domenico Albano; Francesco Dondi; Francesco Bertagna; Valentina Garibotto; Jolanta Kunikowska; Arnoldo Piccardo; Salvatore Annunziata; Vittoria Espeli; Denis Migliorini; Giorgio Treglia
Journal:  Diagnostics (Basel)       Date:  2022-07-08

7.  [68Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma.

Authors:  Peter Truckenmueller; Josefine Graef; Michael Scheel; Peter Vajkoczy; David Capper; David Kaul; Christian Furth; Holger Amthauer; Winfried Brenner; Julia Sophie Onken
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

Review 8.  A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Authors:  Julie Bolcaen; Janke Kleynhans; Shankari Nair; Jeroen Verhoeven; Ingeborg Goethals; Mike Sathekge; Charlot Vandevoorde; Thomas Ebenhan
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.